logo
Apple hits out at pornography app allowed onto EU iPhones

Apple hits out at pornography app allowed onto EU iPhones

Yahoo05-02-2025
Apple has hit out at a newly launched pornography app available on the iPhone in the EU, warning digital competition rules in Europe could undermine user safety and consumer confidence.
Earlier this week, AltStore PAL, an alternative app marketplace now accessible on EU-based iPhones because of European competition laws introduced in 2023, unveiled an adult content browser called Hot Tub.
In a social media post, AltStore called Hot Tub 'the world's first Apple-approved porn app'.
Apple rejected that description and hit back at AltStore, saying it would never allow such an app on its own App Store, and that it is required by the European Commission under the Digital Markets Act to allow other marketplaces to operate in the EU.
Under Apple's rules, apps on alternative app stores still have to go through a certification process called notarisation to ensure they meet 'baseline platform integrity standards', but after that it is the decision of the marketplace itself whether to publish the app in question.
In a statement, Apple said: 'We are deeply concerned about the safety risks that hardcore porn apps of this type create for EU users, especially kids.
'This app and others like it will undermine consumer trust and confidence in our ecosystem that we have worked for more than a decade to make the best in the world.
'Contrary to the false statements made by the marketplace developer, we certainly do not approve of this app and would never offer it in our App Store.'
Under the Digital Markets Act, tech giants are required to open up their services to more competition, including allowing smartphone users to access content and apps from alternative sources, instead of being limited to the native Apple App Store or Google's Play Store.
AltStore hit back at Apple in a further statement of its own, saying it was 'not true' that it had made 'false statements about the approval of Hot Tub'.
'All apps distributed with AltStore PAL must be submitted to Apple for 'notarisation',' it said in a post on its social media channels.
'Unlike macOS, iOS notarisation involves a human-review process where Apple employees manually review apps before they are 'approved' or 'rejected' for distribution (in Apple's own words).
'Unfortunately, Apple has rejected several apps from our store in the past for dubious reasons, so the phrase 'Apple-approved' in our marketing is a reference to the fact that Hot Tub was approved, not rejected, by Apple for notarisation.
'To be perfectly clear, Apple has not endorsed Hot Tub in any way. However, they did approve it.'
AltStore is backed by Fortnite maker Epic Games, which has been embroiled in a years-long battle with Apple over app distribution and App Store commission fees for developers.
Epic Games chief executive Tim Sweeney also took to social media to comment on the incident, saying 'this isn't how platforms should work'.
'On Windows, Mac, and Linux, developers can make and release apps without the platform maker adding junk fees and rendering moral judgments on their decisions. On iOS, Apple forces its processes on developers against their wishes,' he said in a post on X.
'We've argued to the European Union that Apple should be forced out of developers' way, because when Apple are allowed to be the gatekeeper of competing apps and stores, they grossly misuse that power to disadvantage competition.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates

Yahoo

time37 minutes ago

  • Yahoo

ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare stocks. ImmunityBio, Inc. (NASDAQ:IBRX) is among the best healthcare stocks. It is a clinical-stage biotech company developing advanced immunotherapies and vaccines targeting cancers and infectious diseases by activating immune cells such as natural killer and T cells. A key recent milestone is the FDA-approved immunotherapy drug ANKTIVA for bladder cancer, specifically for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). ANKTIVA, designated a Breakthrough Therapy, is expanding its clinical use, notably with the Michael E. DeBakey VA Medical Center in Houston becoming one of the first VA hospitals to administer the treatment to veterans, a population at higher bladder cancer risk. In Q2 2025, ImmunityBio, Inc. (NASDAQ:IBRX) reported a 60% revenue growth quarter-over-quarter, reaching $26.4 million and a year-to-date total of approximately $43 million. This growth is driven by increased commercial momentum post-approval and supported by an $80 million capital raise in July 2025 to fuel ongoing development and expansion. ImmunityBio, Inc. (NASDAQ:IBRX) is transitioning from a clinical-stage biotech to a commercial-stage company with ANKTIVA's expanding adoption, including recent UK regulatory approval for ANKTIVA plus BCG. The drug addresses an underserved cancer indication with the potential to reduce invasive treatments like cystectomy, backed by clinical data showing durable bladder preservation up to 36 months in responders. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wall Street Remains Bullish on Apple (AAPL) Amid AI Upside and Resilient Earnings
Wall Street Remains Bullish on Apple (AAPL) Amid AI Upside and Resilient Earnings

Yahoo

time2 hours ago

  • Yahoo

Wall Street Remains Bullish on Apple (AAPL) Amid AI Upside and Resilient Earnings

Apple Inc. (NASDAQ:AAPL) is one of the On August 13, Bank of America reiterated its bullish stance on Dell and Apple in a note to clients. The firm cited early-stage artificial intelligence adoption and a pending PC refresh cycle as key drivers for the sector. Particularly for Apple, it maintained a Buy rating, pointing to 'resilient earnings, strong capital returns and optionality to monetize incremental avenues of growth.' Pixabay/Public Domain Analysts on Wall Street have a consensus Buy rating on the stock. The average price target of $240 implies a 3.2% upside; however, the Street-high target of $275 implies an upside of 18.3%. Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store